Madrigal PharmaceuticalsMDGL
MDGL
About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Employees: 528
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
86% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 36
48% more capital invested
Capital invested by funds: $4.77B [Q3] → $7.08B (+$2.31B) [Q4]
22% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 76
11% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 10 (+1) [Q4]
10% more call options, than puts
Call options by funds: $354M | Put options by funds: $321M
10% more funds holding
Funds holding: 254 [Q3] → 280 (+26) [Q4]
0.8% more ownership
Funds ownership: 104.42% [Q3] → 105.22% (+0.8%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$405
23%
upside
Avg. target
$434
31%
upside
High target
$469
42%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Citigroup David Lebovitz 75% 1-year accuracy 12 / 16 met price target | 42%upside $469 | Buy Maintained | 27 Feb 2025 |
HC Wainwright & Co. Ed Arce 47% 1-year accuracy 71 / 152 met price target | 23%upside $405 | Buy Maintained | 27 Feb 2025 |
JMP Securities Jonathan Wolleben 0 / 0 met price target | 29%upside $427 | Market Outperform Reiterated | 10 Jan 2025 |
Financial journalist opinion
Based on 10 articles about MDGL published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Madrigal Appoints Jacqualyn A. Fouse, Ph.D.
Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa.
Positive
Seeking Alpha
3 weeks ago
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's Phase 3 trial aims to expand Rezdiffra's label to early cirrhosis by 2027, with EMA approval expected in mid-2025. GLP-1s like semaglutide and tirzepatide show promising MASH results, potentially disrupting Rezdiffra's market despite its first-mover advantage.
Positive
Zacks Investment Research
4 weeks ago
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Positive
Benzinga
4 weeks ago
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).
Positive
Seeking Alpha
4 weeks ago
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target.
Positive
The Motley Fool
4 weeks ago
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday.
Neutral
Seeking Alpha
4 weeks ago
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 weeks ago
Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago.
Neutral
GlobeNewsWire
4 weeks ago
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights.
Neutral
GlobeNewsWire
4 weeks ago
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reported positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom). Patients treated with Rezdiffra achieved marked reductions in liver stiffness, a surrogate for fibrosis, measured by vibration-controlled transient elastography (VCTE).
Charts implemented using Lightweight Charts™